Trial
NCT00431340
A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma
Phase IITERMINATEDSAFETYConfidence: HIGH
Sponsor
Valerio Therapeutics
Collaborators
—
Condition
Multiple Myeloma
Intervention
PXD101
Why stopped
Terminated due to dose limiting toxicity
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2015-07-08